Stanley N N
Eur J Respir Dis Suppl. 1986;146:635-9.
The effects on respiratory regulation of giving almitrine bismesylate (100 mg daily) orally for four weeks in twelve patients with chronic airflow obstruction were assessed in a double-blind placebo-controlled study. The drug caused significant increases in ventilation and the ventilatory response to hypoxia, associated with partial relief of arterial hypoxaemia and a fall in arterial CO2 tension. No consistent changes occurred with placebo. The results are in accord with a sustained action of almitrine bismesylates sensitising peripheral chemoreception.